New hope for Hard-to-Treat cancers: drug combo targets PTEN loss
NCT ID NCT07446049
First seen Mar 05, 2026 · Last updated May 12, 2026 · Updated 6 times
Summary
This study tests a combination of two drugs (CVL237 and serplulimab) in people with advanced solid tumors that have lost or have low levels of a protein called PTEN. The goal is to see if this treatment can shrink tumors or slow their growth. About 180 adults whose cancer has worsened after standard therapy will participate. The study is not yet recruiting.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LOCALLY ADVANCED OR METASTATIC SOLID TUMORS are added.
By submitting, you agree to our Terms of use
Conditions
Explore the condition pages connected to this study.